Evaluating the Safety and Efficacy of Our Products

Clinical Development

Developing new drugs from the laboratory to the marketplace takes years to complete. The process is designed to ensure patient safety and must follow strict regulations governing the evaluation of safety and efficacy.

The clinical trial, a study of patients who volunteer to receive an investigational drug and to be followed closely to observe the drug’s effects, is one of the most important steps in the process of developing new medicines. Only by carefully studying drug candidates in humans can we begin to understand their potential benefits and risks.

In 2017, Sangamo is conducting four clinical trials for its lead programs evaluating the safety and tolerability of treatments for Hemophilia A, Hemophilia B, MPS I and MPS II. Please visit the Clinicaltrials.gov webpage to learn more about our clinical trials.

Hemophilia

SB-FIX-1501

SB-FIX-1501

In 2017 Sangamo is conducting a Phase 1/2 clinical trial to evaluate safety, tolerability and preliminary efficacy in Hemophilia B. Please visit the Clinicaltrials.gov webpage to learn more about our clinical trials.

Lysosomal Storage Disorders

SB-318-1502

SB-318-1502

In 2017 Sangamo is conducting a Phase 1/2 clinical trial to evaluate safety, tolerability and preliminary efficacy in MPS I. Please visit the Clinicaltrials.gov webpage to learn more about our clinical trials.

HIV/AIDS

SB-728mR-HSPC

SB-728mR-HSPC

An investigator sponsored Phase 1/2 clinical trial is ongoing at City of Hope to evaluate safety, tolerability and preliminary efficacy of this treatment in HSPCs. Please visit the Clinicaltrials.gov webpage to learn more about our clinical trials in HIV/AIDS.